ADPTAdaptive Biotechnologies Corporation

ADPT Stock Price, Valuation & Chart | Adaptive Biotechnologies Corporation

Compare

$24.660+0.32 (+1.31%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ADPT intrinsic value ADPT calculated fair value vs price

Overview Financials Dividends Ratios

ADPT Historical price chart

ADPT Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization3.95B

PE Ratio-60.15

EPS-0.41

Trading Volume1.62M

Today's High/Low25.23/24.18

Dividend Yield0.00

52 Week High/Low26.87/12.0

Shares Outstanding160.04M

ADPT Financial Statement

ADPT Analyst ratings

ADPT Analysis & performance metrics

ADPT Company profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers…

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation…

ADPT Management team

Name

Position

Harlan S. Robins Ph.D.

Co-Founder & Chief Scientific Officer

Francis T. Lo

Chief People Officer

Julie RubinsteinCOO

President & Chief Operating Officer

Kyle PiskelCFO

Vice President, Chief Financial Officer & Principal Accounting Officer

Sharon Benzeno Ph.D.

Chief Commercial Officer of Immune Medicine

Christopher Carlson Ph.D.

Founder

Karina Calzadilla

Vice President of Investor Relations

Susan Bobulsky

Chief Commercial Officer of MRD

Name

Position

Harlan S. Robins Ph.D.

Co-Founder & Chief Scientific Officer

Francis T. Lo

Chief People Officer

Julie RubinsteinCOO

President & Chief Operating Officer

Kyle PiskelCFO

Vice President, Chief Financial Officer & Principal Accounting Officer

Sharon Benzeno Ph.D.

Chief Commercial Officer of Immune Medicine

Christopher Carlson Ph.D.

Founder

Karina Calzadilla

Vice President of Investor Relations

Susan Bobulsky

Chief Commercial Officer of MRD

Management Team

Harlan S. Robins Ph.D.

Co-Founder & Chief Scientific Officer

Francis T. Lo

Chief People Officer

Julie RubinsteinCOO

President & Chief Operating Officer

Kyle PiskelCFO

Vice President, Chief Financial Officer & Principal Accounting Officer

Sharon Benzeno Ph.D.

Chief Commercial Officer of Immune Medicine

Christopher Carlson Ph.D.

Founder

Karina Calzadilla

Vice President of Investor Relations

Susan Bobulsky

Chief Commercial Officer of MRD

Management

Harlan S. Robins Ph.D.

Co-Founder & Chief Scientific Officer

Francis T. Lo

Chief People Officer

Julie RubinsteinCOO

President & Chief Operating Officer

Kyle PiskelCFO

Vice President, Chief Financial Officer & Principal Accounting Officer

Sharon Benzeno Ph.D.

Chief Commercial Officer of Immune Medicine

Christopher Carlson Ph.D.

Founder

Karina Calzadilla

Vice President of Investor Relations

Susan Bobulsky

Chief Commercial Officer of MRD

Total 8 executives

ADPT Frequently asked questions

What is Adaptive Biotechnologies Corporation (ADPT) Stock Price?

Current stock price of Adaptive Biotechnologies Corporation (ADPT) stock is $24.660. The stock price is +1.31% higher in the session. The intraday range can be seen from this page. Volume of Adaptive Biotechnologies Corporation (ADPT) stock is 1.62M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Adaptive Biotechnologies Corporation (ADPT) stock price going up or down today?

The stock price of Adaptive Biotechnologies Corporation (ADPT) can change with earnings, company news, and overall market sentiment. Adaptive Biotechnologies Corporation operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Adaptive Biotechnologies Corporation stock expensive at its current price?

Whether Adaptive Biotechnologies Corporation looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ADPT on this page is -60.15. EPS on this page is -0.41. Compare those figures with peers and growth expectations before deciding if the current Adaptive Biotechnologies Corporation price is justified.

How has the stock price of Adaptive Biotechnologies Corporation (ADPT) performed historically?

Historical performance for Adaptive Biotechnologies Corporation (ADPT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ADPT reacted to past earnings and market events.

Should I buy Adaptive Biotechnologies Corporation (ADPT) stock, at this price?

Buying Adaptive Biotechnologies Corporation (ADPT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.